The cardiovascular biomarker conundrum: Challenges and solutions

JAMA

Volumn 306, Issue 19, 2011, Pages 2151-2152

  Prasad, Vinay ^a   Bonow, Robert O ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ENCAINIDE; FLECAINIDE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MORACIZINE; PLACEBO; ROSUVASTATIN; TORCETRAPIB;

CARDIOVASCULAR DISEASE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DISEASE MARKER; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE EXTRASYSTOLE; HUMAN; ISCHEMIC HEART DISEASE; MYOCARDIAL PERFUSION IMAGING; NOTE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; STRESS ECHOCARDIOGRAPHY; SUDDEN DEATH;

EID: 81255147402     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.1673     Document Type: Note

References (10)

1. Biomarkers Definitions Working Group. Biomarkers and surrogate end points: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3):89-95.
2. Somberg JC. New directions in antiarrhythmic drug therapy. Am J Cardiol. 1984; 54:8-17.
3. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324(12):781-788.
4. Barter PJ, Caulfield M, Eriksson M, et al. ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007; 357(21):2109-2122. (Pubitemid 350146106)
5. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97(18):1837-1847. (Pubitemid 28213628)
6. Tzoulaki I, Liberopoulos G, Ioannidis JP. Assessment of claims of improved prediction beyond the Framingham risk score. JAMA. 2009;302(21):2345- 2352.
7. Polonsky TS, McClelland RL, Jorgensen NW, et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA. 2010;303 (16):1610-1616.
8. Bonow RO, Maurer G, Lee KL, et al. STICH Trial Investigators. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med. 2011; 364(17):1617-1625.
9. Ridker PM, Danielson E, Fonseca FAH, et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207.
10. Ray KK, Seshasai SRK, Erqou S, et al. Statins and all-cause mortality in highrisk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65 229 participants. Arch Intern Med. 2010;170(12):1024-1031.